Abstract: OBJECTIVE To explore the clinical effect of tigecycline on treatment of pandrug-resistant Acinetobacter baumannii infection in patients with ventilator-associated pneumonia. METHODS From Jul 2012 to Mar 2014, a total of 16 senile patients with confirmed severe pandrug-resistant A.baumannii ventilator-associated pneumonia were treated with 100 mg of tigecycline for the first dose, followed by 50 mg for each time, intravenous drip every 12 hours; meanwhile the combined medication with sulbactam or carbapenems or single medication was conducted for 10-14 days.The symptoms, signs, blood routines, hepatic and renal function, chest X ray, sputum culture, and drug-induced adverse reactions of all the patients were monitored during the treatment. RESULTS Of the 16 patients, 4 died, 5 were cured, and 7 were effective, with the total effective rate 75.0%.The result of the bacterial culture showed that the strains were cleared in 10 of 16 patients but were not cleared in 6 cases.The imageological findings of the 5 cases of the cured and 7 cases of the effective were remarkably improved, while the imageological findings of the dead cases showed aggravation or exacerbation.Three patients had mild liver function damage and were cured after active liver protection. CONCLUSION The single or combined use of tigecycline can achieve significant effect on treatment of the pandrug-resistant A.baumannii infection in the patients with severe ventilator-associated pneumonia, with the safety high.